Keybank National Association Supernus Pharmaceuticals, Inc. Transaction History

Keybank National Association

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 05, 2020	SELL	$19.93 - $29.13 $154,477 - $225,786	-7,751 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$25.47 - $33.37 $202,486 - $265,291	-7,950 Reduced 50.63%	7,751 $213,000
Q2 2019 Aug 01, 2019	SELL	$29.96 - $38.87 $219,816 - $285,189	-7,337 Reduced 31.85%	15,701 $520,000
Q1 2019 May 08, 2019	SELL	$32.77 - $41.99 $131,899 - $169,009	-4,025 Reduced 14.87%	23,038 $807,000
Q4 2018 Jan 30, 2019	BUY	$30.84 - $49.51 $339,980 - $545,798	11,024 Added 68.73%	27,063 $899,000
Q3 2018 Nov 08, 2018	SELL	$42.7 - $56.55 $131,046 - $173,551	-3,069 Reduced 16.06%	16,039 $808,000
Q2 2018 Aug 08, 2018	BUY	$44.1 - $59.85 $842,662 - $1.14 Million	19,108 New	19,108 $1.14 Million
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $887,402 - $1.12 Million	-23,887 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$36.4 - $42.6 $36,654 - $42,898	1,007 Added 4.4%	23,887 $952,000
Q3 2017 Nov 02, 2017	BUY	$36.75 - $49.65 $840,840 - $1.14 Million	22,880	22,880 $915,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.96B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

Stay updated on Keybank National Association with notifications on news.